Please assess the completion status of the following clinical trial:

Trial Title: Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed and dated written informed consent~2. Males and females ≥ 12 years of age~3. HbA1c ≤ 12%~4. Insulin pump use for at least 3 months~5. Clinical diagnosis with type 1 diabetes for at least 12 months. The diagnosis of T1D is based on the investigator's clinical judgment; C peptide level and antibody determinations are not planned.~6. Women of child-bearing potential must be ready and able to use a highly effective method of birth control. Women of childbearing potential are females who have experienced \[the first occurrence of menstruation\] and do not meet the criteria for women not of childbearing potential. Women not of childbearing potential are females who are permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.~Exclusion Criteria:~Participants who meet any of the following criteria are not eligible for the study:~1. Current or ≤ 1 month use of other antihyperglycemic agents (SGLT2 inhibitors, GLP-1 agonists, Metformin, Acarbose, etc....).~2. Current use of glucocorticoid medication.~3. Use of medication that alters gastrointestinal motility.~4. Planned or ongoing pregnancy.~5. Breastfeeding individuals.~6. Severe hypoglycemic episode within one month of admission.~7. Severe diabetes ketoacidosis episode within one month of admission.~8. Clinically significant nephropathy, neuropathy or retinopathy as judged by the investigator.~9. Recent (\< 6 months) acute macrovascular event e.g. acute coronary syndrome or cardiac surgery.~10. Known hypersensitivity to any of the study drugs or their excipients.~11. Individuals with confirmed gastroparesis.~12. Other serious medical illness likely to interfere with study participation or with the ability to complete the trial by the judgment of the investigator.~13. Unable to travel to research center within 3h if needed during study interventions~14. Failure to comply with team's recommendations (e.g. not willing to eat meals/snacks, not willing to change pump parameters, etc.).~Study Discontinuation/Withdrawal~1. Failure to comply with the protocol.~2. Pregnancy.~3. After an event which the PI believes it is not in the best interest for the patient to continue the trial.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fiasp-plus-Placebo with Full Carbohydrate Counting (Type: EXPERIMENTAL): Fiasp insulin and placebo insulin infusion in two insulin pumps with full carbohydrate counting.
- Fiasp-plus-placebo with Simple Meal Announcement (Type: PLACEBO_COMPARATOR): Fiasp insulin and placebo (saline) insulin infusion in two insulin pumps using the simple meal announcement system.
- Fiasp-plus-Pramlintide with Simple Meal Announcement (Type: ACTIVE_COMPARATOR): Fiasp insulin and pramlintide insulin infusion in two insulin pumps using the simple meal announcement system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete